Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

t over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there were an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse, and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc. All other trademarks appearing in this release are the property of their respective owners.

This press rele
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... 10 ,Anesiva, Inc. (Nasdaq: ANSV ) today ... Drug Application (sNDA) with the U.S. Food and ... to treat the pain,associated with peripheral IV insertions ... powder intradermal,injection system is already approved by the ...
... based on data previously reported, communicated in late 2007 ... ... 7 Ortho Biotech Products, L.P.,today modified prescribing information for PROCRIT(R) (Epoetin ... for all drugs within the erythropoiesis-stimulating agent,(ESA) class., Modifications to the ...
... West Pharmaceutical,Services, Inc. (NYSE: WST ) today announced ... Day event on Thursday, March 13, 2008 from 8:30am,to ... the Grand Hyatt,Hotel in New York, New York., ... look at,the Company,s global operations, business segments, supply chain ...
Cached Biology Technology:Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 2Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 3Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7West to Host Investor Day 2
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces it ... Robbins for the 2015 International CES debut of the ... will be at the NXT-ID booth January 6th and ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... and sea slug expert at the California Academy of ... by the Encyclopedia of Life (EOL). These early-career ... their biodiversity research with colleagues and the general public. ... international collaboration that aims to provide freely accessible information ...
... , MOUNTAIN VIEW, CA January 11, 2011 23andMe ... to be the 10 most interesting and significant genetic findings ... the role of genetics in personal health and human development. ... at a phenomenal rate," stated Anne Wojcicki, co-founder and CEO ...
... cafeteria lines to their menu of tools to help ... U.S. Department of Agriculture recently awarded $40,000 from the ... Conklin, associate professor, hospitality management; and Lisa Bailey-Davis, senior ... project will use economic concepts to study the effect ...
Cached Biology News:Encyclopedia of Life names Dr. Rebecca Johnson a 2011 Rubenstein Fellow 2Encyclopedia of Life names Dr. Rebecca Johnson a 2011 Rubenstein Fellow 323andMe presents top 10 most interesting genetic findings of 2010 223andMe presents top 10 most interesting genetic findings of 2010 323andMe presents top 10 most interesting genetic findings of 2010 423andMe presents top 10 most interesting genetic findings of 2010 523andMe presents top 10 most interesting genetic findings of 2010 623andMe presents top 10 most interesting genetic findings of 2010 723andMe presents top 10 most interesting genetic findings of 2010 823andMe presents top 10 most interesting genetic findings of 2010 923andMe presents top 10 most interesting genetic findings of 2010 1023andMe presents top 10 most interesting genetic findings of 2010 1123andMe presents top 10 most interesting genetic findings of 2010 1223andMe presents top 10 most interesting genetic findings of 2010 1323andMe presents top 10 most interesting genetic findings of 2010 1423andMe presents top 10 most interesting genetic findings of 2010 1523andMe presents top 10 most interesting genetic findings of 2010 1623andMe presents top 10 most interesting genetic findings of 2010 1723andMe presents top 10 most interesting genetic findings of 2010 18Quick school cafeteria lines could lead to healthier food choices 2
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: